Retention rate of Levetiracetam in children with intractable epilepsy at 1 year

Seizure

Volumn 16, Issue 2, 2007, Pages 185-189

  Peake, D ^a   Mordekar, S ^b   Gosalakkal, J ^c   Mukhtyar, B ^d   Buch, S ^a   Crane, J ^a   Wheway, R ^d   Rittey, C ^b   Donnelly, J ^d   Whitehouse, W P ^d,e   Philip, S ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^b SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Children; Clinical audit; Intractable epilepsies; Levetiracetam

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PREDNISOLONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADOLESCENT; ADULT; AGGRESSION; ARTICLE; BEHAVIOR; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG RETENTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMOTIONALITY; FEMALE; FOLLOW UP; HUMAN; INFANT; INTRACTABLE EPILEPSY; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MONOTHERAPY; NAUSEA; OBSERVATIONAL STUDY; ONSET AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; SIDE EFFECT; SOMNOLENCE; SYMPTOM; VOMITING;

ADOLESCENT; ADOLESCENT BEHAVIOR; ANTICONVULSANTS; CHILD; CHILD BEHAVIOR; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; INFANT; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PATIENT DROPOUTS; PIRACETAM; RETROSPECTIVE STUDIES;

EID: 33846803993     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2006.12.001     Document Type: Article

References (24)

1. Klitgaard H., Matagne A., Gobert G., and Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353 (1998) 191-206
2. Bulacio J., Sfaello I., and Sfaello Z. Clinical experience with Levetiracetam in children with intractable epilepsy. Epilepsia 7 October (Suppl. 45) (2004) 317 [Abstract 2.372]
3. Bourgeois B.F.D., Holder D.L., Valencia I., Holmes G.L., Riviello J.J., Thiele E.A., et al. Open -label assessment of levetiracetam efficacy and adverse effects in a paediatric population. Epilepsia 42 November (Suppl. 7) (2001) 53-54 [Abstract 1.166]
4. Lagae L., Buyse G., and Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure January (14) 1 (2005) 66-71
5. Lagae L., Buyse G., Deconinck A., and Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediat Neurol 7 3 (2003) 123-128
6. Wheless J.W. Using the new antiepilepsy drugs in children. J Child Neurol 17 January (Suppl. 1) (2002) S58-S64
7. Opp J., Tuxhorn I., May T., Kluger G., Wiemer-Kruel A., Krulmann G., et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 14 October (7) (2005) 476-484 [Epub 2005 September 22]
8. Koukkari M.W., and Guarino E.J. Retrospective study of the use of levetiracetam in childhood seizures disorders. J Child Neurol 19 12 (2004) 944-947
9. Pellock J.M., Glauser T.A., Bebin M.E., Fountain N.B., Ritter F.J., Coupez R.M., et al. Pharmacokinetic study of Levetiracetam in children. Epilepsia 42 12 (2001) 1574-1579
10. Glauser T.A., Pellock J.M., Bebin M.E., Fountain N.B., Ritter F.J., Jensen C.M., et al. Efficacy and safety of Levetiracetam in children with partial seizures: an open label trial. Epilepsia 43 (2002) 518-524
11. Briggs D.E., and French J.A. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Safety September (5) (2004) 415-424
12. Besag F.M. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Safety 3 January (1) (2004) 1-8
13. Besag F.M. Behavioural effects of the new anticonvulsants. Drug Safety 24 7 (2001) 513-536
14. Bourgeois B.F.D. Determining the effects of antiepileptic drugs on cognitive function in pediatric patients with epilepsy. J Child Neurol 19 Suppl. 1 (2004) S15-S25
15. Ben-Menachem E., and Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 12 April (3) (2003) 131-135
16. Mohanraj R., Parker P.G., Stephen L.J., and Brodie M.J. Levetiracetam in refractory epilepsy: a prospective observational study. Seizure 14 January (1) (2005) 23-27
17. Glauser T.A. Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients. J Child Neurol 19 August (Suppl. 1) (2004) S25-S38
18. Glauser T.A., Gauer L.J., and Chen L. Multicentre, double-blind, placebo controlled trial of adjunctive levetiracetam (keppra®) therapy (up to 60 mg/kg/day) in pediatric patients with refractory partial epilepsy. Epilepsia 7 October (Suppl. 45) (2004) 186 [Abs. B.03]
19. Coppola G., Mangano S., Tortorella G., Pelliccia A., Fels A., Romano A., et al. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Epilepsy Res 59 1 (2004, Mar) 35-42
20. Krakow K., Walker M., Otoul C., and Sander J.W.A.S. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56 June (12) (2001) 1772-1774
21. Mandelbaum D.E., Bunch M., Kugler S.L., Venkatasubramanian A., and Wollack J.B. Efficacy of levetiracetam at 12 months in children classified by seizure type, cognitive status, and previous anticonvulsant drug use. Child Neurol 20 July (7) (2005) 590-594
22. Lhatoo S.D., Wong I.C., Polizzi G., and Sander J.W. Long-term retention rates of lamotrogine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 41 December (12) (2000) 1592-1596
23. Stoner S.C., Lea J.W., Wolf A.L., and Berges A.A. Levetiracetam for mood stabilization and maintenance of seizure control following multiple treatment failures. Ann Pharmacother 39 November (11) (2005) 1928-1931
24. Kelly K., Stephen L.J., and Brodie M.J. Levetiracetam for people with mental retardation and refractory epilepsy. Epilepsy Behav 5 6 (2004, Dec) 878-883